Biosimilar Development News

  1. Kamada Enters Into Two New Agreements For The Distribution Of Three Biosimilar Products In Israel 1/13/2021

    Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced that the Company has entered into agreements with two undisclosed international pharmaceutical companies to commercialize three biosimilar product candidates in Israel.

  2. Henlius Daratumumab Biosimilar Received IND Approval From NMPA 1/13/2021

    Shanghai Henlius Biotech, Inc. (2696.HK) announced that the Investigational New Drug (IND) application of the Company's daratumumab biosimilar HLX15, a recombinant anti-CD38 fully human monoclonal antibody injection, for the treatment of multiple myeloma (MM) has been approved by the National Medical Products Administration (NMPA).

  3. Sudarshan Jain Takes Over The Position Of IGBA Chair 1/11/2021

    IGBA, the International Generic and Biosimilar Medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, announced today that Sudarshan Jain, Secretary General of the Indian Pharmaceutical Alliance (IPA), is taking over the position of IGBA Chair for 2021 from Hanan Sboul, Secretary General of the Jordanian Association of Pharmaceutical Manufacturers.

  4. Global Rituximab Biosimilars Market Report 2020-2030: COVID-19 Impacts, Growth And Change 1/7/2021

    The "Rituximab Biosimilars Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

  5. Biocon Biologics Receives Rs 555 Cr (USD 75 Million) Capital Injection From ADQ 1/7/2021

    Biocon Ltd, an innovation-led global biopharmaceuticals company, today announced that the Board of its subsidiary Biocon Biologics Ltd (“Biocon Biologics”) has approved a primary equity investment by Abu Dhabi based ADQ (“ADQ”), one of the region’s largest holding companies.

  6. Xbrane Re-Negotiates Pre-Existing IP License Agreement With Vaxiion Therapeutics 1/5/2021

    Xbrane Biopharma AB (publ) (“Xbrane Biopharma” or the “Company”) has re-negotiated a pre-existing license agreement of certain intellectual property rights, mainly patent US7871815B2, with Vaxiion Therapeutics.

  7. Ground-Breaking For The Extension Of Alvotech's High-Tech Centre In Reykjavik 12/30/2020

    A ground-breaking ceremony for the extension of Alvotech's high-tech centre in Reykjavík took place today. Robert Wessman, Chairman of the Board, Dagur B. Eggertsson, Mayor of Reykjavik and Jon Atli Benediktsson, Rector of the University of Iceland, took the first shoveling together with key employees who have been involved in the project.

  8. Innovent Announces The NMPA Granted New Indication Approval For BYVASDA® (Bevacizumab Biosimilar) For The Treatment Of Adult Recurrent Glioblastoma 12/27/2020

    Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announces that BYVASDA® (bevacizumab biosimilar), a recombinant humanized anti-VEGF monoclonal antibody drug independently developed by Innovent, has been officially approved by the National Medical Products Administration (NMPA) of China for the treatment of adult recurrent glioblastoma (GBM, the most common malignant primary brain tumor), which is the third approved indication of BYVASDA® in China.

  9. Innovent Announces NMPA Granted New Indication Approvals For SULINNO® (Adalimumab Injection) For The Treatment Of Pediatric Plaque Psoriasis And Non-Infectious Uveitis 12/22/2020

    Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announces that SULINNO® (adalimumab injection), a recombinant human anti-TNF-α monoclonal antibody drug, has been officially approved by the National Medical Products Administration (NMPA) of China for two new indications, including the treatment of pediatric plaque psoriasis and non-infectious intermediate uveitis, posterior uveitis and panuveitis in adults who do not respond adequately to corticosteroids, require restraint of corticosteroids, or are not suitable for corticosteroid therapies.

  10. Biosimilar Interleukins Global Market Report 2020-30: COVID-19 Growth And Change 12/21/2020

    83 billion in 2019 to $1.6 billion in 2020 at a compound annual growth rate (CAGR) of 93.0%. The slow growth despite being launched in 2019 is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges.